In vivo evaluation of phage therapy against Klebsiella pneumoniae using the Galleria mellonella model and molecular characterization of a novel Drulisvirus phage species
Microbiology Spectrum · 06.05.2025 · 13 (5)
DOI: 10.1128/spectrum.01145-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 06.05.2025. Verfasst von Gustavo Quispe-Villegas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Resistencia Antibiótica y Fagoterapia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias e Ingeniería, Universidad Peru…. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Klebsiella Infections, Phage Therapy, Bacteriophages. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Multidrug-resistant (MDR) Klebsiella pneumoniae is challenging to treat with conventional antibiotic regimens, posing a threat to healthcare systems. Phage therapy presents a promising alternative treatment strategy; however, characterization of its efficacy and safety is required. Here, we describe the microbiological and molecular characterization of a novel bacteriophage with activity against MDR K. pneumoniae using a greater wax moth ( Galleria mellonella ) model system. A bacteriophage was isolated from hospital wastewater. Viral kinetics and phage stability were evaluated under varied pH and temperature conditions. The therapeutic efficacy of the phage was evaluated using MDR Klebsiella -infected G. mellonella larvae as an in vivo model. Phage titers and larva survival were compared in phage-treated and control groups. Genomic sequencing (Nanopore and Illumina) was used to classify the bacteriophage and identify any resistance genes or virulence factors present in its genome. Functional characterization demonstrated effective lytic activity, favorable burst size (161 PFU/cell), and an optimal MOI of 0.1. The phage demonstrated stability across a wide range of temperatures (8°C–40°C) and pH levels ( 4 – 8 ). Experiments using the G. mellonella model showed improved larval survival with phage treatment. The novel bacteriophage was identified as a new species within the genus Drulisvirus with no lysogeny-associated, antimicrobial resistance, or virulence genes detected. The new Drulisvirus phage identified is a promising candidate for treatment of infections caused by MDR K. pneumoniae . IMPORTANCE The study describes a bacteriophage with potential for use in phage therapy against Klebsiella pneumoniae , one of the most clinically significant bacterial pathogens today. Microbiological and genomic characterization of the phage revealed advantageous properties for therapeutic applications, while also identifying a novel species within the Drulisvirus genus. These findings significantly contribute to our understanding of bacteriophage diversity and their utility in combating antibiotic-resistant infections. Moreover, the authors developed an in vivo preclinical model of MDR infection using Galleria mellonella larvae and successfully applied it to study the bacteriophage’s therapeutic efficacy. This model offers a robust and efficient platform for preclinical testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratorio de Resistencia Antibiótica y Fagoterapia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia, Lima, Peru.
- Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Peru.
- Laboratorio de Genómica Microbiana, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia, Lima, Peru.
- Laboratorio de Moléculas Individuales, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia, Lima, Peru.
- Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
- Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, United Kingdom.
ORCID-Profile: Gustavo Quispe-Villegas, Pablo Tsukayama, Jesús Tamariz
Zitieren
APA
Quispe-Villegas, G., Alcántara-Lozano, G. I., Cuicapuza, D., Laureano, R., Ayzanoa, B., Tsukayama, P., & Tamariz, J. (2025). In vivo evaluation of phage therapy against Klebsiella pneumoniae using the Galleria mellonella model and molecular characterization of a novel Drulisvirus phage species. Microbiology Spectrum, 13(5). https://doi.org/10.1128/spectrum.01145-24
Vancouver
Quispe-Villegas G, Alcántara-Lozano GI, Cuicapuza D, Laureano R, Ayzanoa B, Tsukayama P, et al. In vivo evaluation of phage therapy against Klebsiella pneumoniae using the Galleria mellonella model and molecular characterization of a novel Drulisvirus phage species. Microbiology Spectrum. 2025;13(5). doi:10.1128/spectrum.01145-24
BibTeX
@article{QuispeVillegas2025,
author = {Quispe-Villegas, Gustavo and Alcántara-Lozano, Gabriela I and Cuicapuza, Diego and Laureano, Raúl and Ayzanoa, Brenda and Tsukayama, Pablo and Tamariz, Jesús},
title = {In vivo evaluation of phage therapy against Klebsiella pneumoniae using the Galleria mellonella model and molecular characterization of a novel Drulisvirus phage species},
journal = {Microbiology Spectrum},
year = {2025},
volume = {13},
number = {5},
doi = {10.1128/spectrum.01145-24}
}
EUVIMED